# Bristol Myers Squibb的口服藥物mezigdomide在醫學界引起關注。

*biotech · news · 2026-05-30 · Devdiscourse*

## Key points

- Mezigdomide在試驗中將多發性骨髓瘤進展或死亡風險降低了52%。
- CVS Health已恢復對Eli Lilly的Zepbound及新批准口服藥Foundayo的保險覆蓋。
- CVS的覆蓋決定源自與其直接競爭對手Novo Nordisk的價格談判。
- 美國在肯亞設立伊波拉隔離設施的提案因當地司法行動而被中止。

Bristol Myers Squibb's innovative oral drug mezigdomide is making waves in the medical community. In a late-stage trial, the drug effectively delayed the progression of multiple myeloma in patients unresponsive to other treatments, cutting the risk of disease progression or death by 52%. CVS Health reinstated coverage for Eli Lilly's obesity drug Zepbound along with its newly approved obesity pill, Foundayo. This decision comes after negotiations regarding pricing with competing drugmaker Novo Nordisk, highlighting the strategic battles within the pharmaceutical industry. In Kenya, a U.S. plan to establish an Ebola quarantine facility met judicial roadblocks, questioning its potential public health risks. The suspension reflects ongoing global concerns about Ebola's spread and the measures being undertaken to control it. (With inputs from agencies.)

**Companies:** Bristol Myers Squibb, CVS Health, Eli Lilly, Novo Nordisk
**Countries:** United States, Kenya

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3926672-myeloma-drug-shows-promise-cvs-backs-obesity-treatments-kenya-ebola-quarantine-raises-concerns)

---

Canonical: https://newsio.io/zh-TW/n/a84985a0-48f6-4f08-88db-200b76e9852f/bristol-myers-squibbmezigdomidecvs-healtheli-lillyzepbound
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works